TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Virological Response (Intention to Treat)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Virological Response Category (Per Protocol)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EGFR T790M mutation prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Prevalence of Iron deficiency (ID stage I)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Prevalence of Iron deficient erythropoiesis (ID stage II)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Prevalence of iron deficiency anemia (ID stage III)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Pharmacodynamic markers of RANKL inhibition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in maximal intimal thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percent of Participants Who Responded to Therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Trough Forced Expiratory Volume in One Second (FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of terminal hairs in the target area of the scalp
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of vellus hairs in the target area of the scalp
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in LV mass index (g/m2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change of Corneal Stiffness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nadir Oxygen Level During Sleep
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of Participants With Any Non-serious Adverse Event (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Area Under the Plasma Concentration Curve (AUC) of GSK3389404
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Major Adverse Cardiac Events (MACE)
Endpoint domain: Adverse events/effects
Primary endpoint: Delay from suspicion of sepsis to optimized antibiotic/antifungal treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in the ventilatory response to hypercapnia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Perceived Stress level
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: degree of Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of microflora
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maintenance of healthy microflora
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of left ventricular hypertrophy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Presence of chronic kidney disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Presence of type 2 diabetes mellitus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Length of time for evaluation for preterm labor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Practice of large bowel irrigation
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Incidence of total drug-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Area under the effect versus time curve for absolute neutrophil count (ANC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Maximum observed value for ANC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Energy balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Problematic hot flushes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ora Calibra Ocular Itching Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ora Calibra Ocular Hyperemia Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ora Calibra Itchy Palate/Mouth Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lab Cost
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Pharmacy Cost
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Radiology Cost
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change from Baseline in Functional Mobility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in Falls
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in Functional Neural Connectivity (fMRI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean Pain50
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of referrals for students identified as suicidal risks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Outcomes of mental health evaluations for accurate detection of suicidal risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in peripheral insulin sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Optimum positive end-expiratory pressure (PEEP) level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of patients with recruitable lung
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Stable allogeneic hematopoietic engraftment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of prostate cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Proportion of Body Mass Gained as Fat-Free Mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Body Mass Gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the Clinical performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Time to Randomization and Initiation of Intervention
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: disappearance of verruca
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Observed Analyte Concentration Just Prior to the Beginning or at the End of a Dosing Interval (Ctrough) of JNJ-63623872
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Analyte Concentration (Cmax) of JNJ-63623872
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Analyte Concentration versus Time Curve (AUC) From Time of Administration up to 12 Hours Post Dosing (AUC12h) of JNJ-63623872
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient-reported severity of chronic pelvic pain
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: 3-month costs per patient
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Classification accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Shoulder Pain and Disability Index (SPADI) scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Difference in final theoretical test score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in final practical test score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resource Utilization - Operating Room/Robotic Studio Time Availability
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Resource Utilization - Cost of Study Participation
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: tinnitus handicap inventory (THI)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: tinnitus functional index (TFI)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes in Lactobacillus and Bifidobacterium populations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Integrity of white matter tracts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Variations of the BOLD signal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in KOOS pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Potentially inappropriate medication use
Endpoint domain: Adverse events/effects
Primary endpoint: MTD determination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Differences in tingling and numbness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: autonomic responsivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Survival at 1 Year
Endpoint domain: Mortality/survival
Primary endpoint: HCV free at 1 year
Endpoint domain: Mortality/survival
Primary endpoint: Parent readiness for hospital discharge
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Post-discharge outcomes
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Maximum tolerated dose (MTD) based on dose-limiting toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Modified Rodnan skin score (mRSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Participation in colorectal cancer screening program
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Physical decline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Capillary refill time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: New morphometric vertebral fractures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: New cases of breast cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: New non-vertebral fractures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Area under the single-dose plasma concentration-time curve (AUC0-t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment response in endometriosis patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Serological markers of HBV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes body weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes body composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in total cholesterol and lipid fractions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: The incidence of Alopecia Areata
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The prevalence of common mental health conditions in adult patients diagnosed with Alopecia Areata
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: The incidence of a composite of common infections in adult patients with Alopecia Areata
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Neuropsychological Status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Hippocampal Volumes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Biomarker NAA/mI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Composite THINC-it Tool Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: CANTAB reaction time (RTI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: 1-back memory task (1-back)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Changes from baseline in neurocognitive function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes from baseline in brain structure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes from baseline in brain function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes from baseline in brain biochemical metabolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cardiac morbidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Clinician-surrogate Concordance Scale Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change From Baseline in Pain Intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Insufficient efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pre-Test Readiness for Postpartum Discharge
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Pre-Test Anxiety Level
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change From Baseline in Ocular Surface Staining
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Shirmer Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of men willing to invite female partner
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Proportion of female partners contacting clinic for enrollment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Proportion of female partners enrolling in study
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: 28 Day mortality
Endpoint domain: Mortality/survival
Primary endpoint: Type, incidence and severity of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Blood concentrations of amoxicillin-clavulanate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood concentrations of piperacillin-tazobactam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood concentrations of temocillin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lung Allocation Score (LAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oswestry Disability Index (ODI) Change
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: safety of GC1008
Endpoint domain: Adverse events/effects
Primary endpoint: Glycemic Control as Measured by HbA1c
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Hamilton Rating Scale of Depression (HRSD)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Hospital anxiety and depression scale (HAD)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in cumulative daily doses of Sifrol®
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in cumulative daily doses of L-dopa
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Visual analog scale (VAS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Participants Who Had a Clinical Response Using the Crohn's Disease Activity Index (CDAI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mean Change From Baseline in Harvey-Bradshaw Index (HBI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Predictive value of 18F-FDG-PET for absence of response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Two-point discrimination test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Participants With Clinical Cure of Lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acute respiratory failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Lipoprotein chemical composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma ghrelin responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma free fatty acids (FFA) responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Stoma Related Cost of Care
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Fugl Myer Test of Upper Extremity Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vital signs and laboratory test results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: short time mortality
Endpoint domain: Mortality/survival
Primary endpoint: Biochemical recurrence-free survival (BCRFS)
Endpoint domain: Mortality/survival
Primary endpoint: Immunosuppressive factors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Patient survival data
Endpoint domain: Mortality/survival
Primary endpoint: antibody decay kinetics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Progression-free Survival at 18 Weeks
Endpoint domain: Mortality/survival
Primary endpoint: clinical response at the TOC assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom from Major Adverse Cardiac Event
Endpoint domain: Mortality/survival
Primary endpoint: Freedom from major arrhythmia
Endpoint domain: Mortality/survival
Primary endpoint: Bioavailability of nalbuphine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Patients Prescribed Appropriate VTE Prophylaxis
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Reduction of Homa Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Population-level Child Obesity as Defined by BMI z-score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pharmacokinetic parameters of MK0431
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients achieving 5mm cervix dilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Humoral Immunity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) at Week 30
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Erythrocytic Sedimentation Rate (ESR) at Week 30
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in C-Reactive Protein (CRP) at Week 30
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ICD Shock Free Survival
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of Salvage Definitive Anti-arrhythmia Therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: stroke volume variation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pelvic congestion pain relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: % of subjects in remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mutational status of the EGFR pathway
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change over time in Patient Rated Wrist Evaluation (PRWE)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: AUC[0-t] of tamsulosin in serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC[0-infinity] of tamsulosin in serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of dutasteride in serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC[0-t] of dutasteride in serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Education learning environment experiences
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Neuropsychological Behavioral Assessment
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: further recurrence
Endpoint domain: Mortality/survival
Primary endpoint: Role Function Scale
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Survival after reintervention
Endpoint domain: Mortality/survival
Primary endpoint: Use of resources and costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use